Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18429013 | 0.87 | CHRM2 (0.49) | KCNH2MGLLMEN1KMT2A | |
| SCHEMBL29979972 | 0.87 | CHRM2 (0.49) | KCNH2MGLLMEN1KMT2A | |
| SCHEMBL9356782 | 0.82 | MEN1 (0.56) | MAPTKCNH2MGLLMEN1KMT2A | |
| SCHEMBL27283741 | 0.77 | KMT2A (0.51) | KCNH2MGLLKMT2A | |
| SCHEMBL27258963 | 0.76 | SRD5A1 (0.48) | KCNH2MGLL | |
| SCHEMBL15537475 | 0.75 | SLC6A4 (0.52) | DPP4DPP7MAPTMGLL | |
| SCHEMBL1256120 | 0.75 | EPHX2 (0.60) | KCNH2 | |
| SCHEMBL28850271 | 0.74 | FAAH (0.50) | KCNH2MGLLFAAH | |
| SCHEMBL27393302 | 0.74 | BLM (0.51) | KCNH2 | |
| SCHEMBL15536002 | 0.74 | FPR2 (0.47) | MAPTMGLLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104520292-B | Sulphonylpiperidine derivant and they are for treating the purposes of disease of front dynein mediation | 武田药品工业株式会社 | 2016-09-14 | — | — | CN | disclosed |